Clinical Trial

Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-02; most recent amendment 2025-06-01.
Status change: Recruiting → Active, Not Recruiting 2025-06-01
Trial Details
NCT Number NCT06541665
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Primary Central Nervous System Lymphoma
Enrollment 20 participants
Start Date 2024-05-17
Primary Completion 2028-04-28 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-03